#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14760	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2087	703.5	0	.	n	.	0	A69G	SNP	69	69	A	289	289	G	825	G,A	754,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14760	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2087	703.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1670	1670	T	822	T,C	750,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	14760	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2087	703.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1404	1404	C	931	C,T	854,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26678	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3512	756.8	0	.	n	.	0	T695C	SNP	695	695	T	970	970	C	809	C,T	741,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26678	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3512	756.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2246	2246	C	884	C	804	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26678	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3512	756.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2320	2320	A	851	A,G	789,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26678	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3512	756.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2872	2872	C	787	C,T,A	726,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	16	14	blaTEM	861	341	99.71	blaTEM.l15.c30.ctg.1	341	1.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Betalactam resistance
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2204	folP	855	855	100.0	folP.l15.c4.ctg.1	1618	135.8	1	SNP	p	R229S	1	.	.	685	687	AGC	1094	1096	AGC	235;235;233	A;G;C	212;212;211	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6304	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3367	186.7	1	SNP	p	S91F	1	.	.	271	273	TTC	578	580	TTC	227;227;228	T;T;C	206;206;208	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6304	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3367	186.7	1	SNP	p	D95G	1	.	.	283	285	GGC	590	592	GGC	230;226;224	G;G,A;C,T	213;210,1;209,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6304	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3367	186.7	1	SNP	p	G95N	0	.	.	283	285	GGC	590	592	GGC	230;226;224	G;G,A;C,T	213;210,1;209,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1840	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1273	143.6	0	.	p	.	0	D79N	NONSYN	235	237	GAT	621	623	AAT	247;245;246	A;A;T	227;225;227	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1840	mtrR	633	633	99.84	mtrR.l15.c30.ctg.1	1273	143.6	1	SNP	p	G45D	0	.	.	133	135	GGC	519	521	GGC	253;254;252	G;G,A;C	235;232,1;234	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1010	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	834	118.9	0	.	n	.	0	A197.	DEL	197	197	A	483	483	A	243	A	220	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5390	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2891	185.5	0	.	p	.	0	E91G	NONSYN	271	273	GAG	635	637	GGG	217;222;223	G;G,A;G	199;202,1;205	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5390	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2891	185.5	1	SNP	p	D86N	0	.	.	256	258	GAC	620	622	GAC	210;209;209	G;A;C,T	195;194;192,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5390	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2891	185.5	1	SNP	p	S87I	0	.	.	259	261	AGT	623	625	AGT	210;205;204	A;G;T	192;189;186	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5390	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2891	185.5	1	SNP	p	S87W	0	.	.	259	261	AGT	623	625	AGT	210;205;204	A;G;T	192;189;186	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5390	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2891	185.5	1	SNP	p	S87R	0	.	.	259	261	AGT	623	625	AGT	210;205;204	A;G;T	192;189;186	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5390	parC	2304	2304	99.87	parC.l6.c4.ctg.1	2891	185.5	1	SNP	p	S88P	0	.	.	262	264	TCC	626	628	TCC	202;203;207	T;C;C	184;186;192	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4916	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2653	184.8	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1614	1616	CAC	234;235;236	C;A;C	213;218;216	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4916	parE	1986	1986	99.95	parE.l6.c4.ctg.1	2653	184.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1563	1565	GGC	246;244;240	G;G;C	224;222;218	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1279	1281	GCA	254;260;262	G;C,T;A	229;237,1;241	penA.44.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1282	1284	ATC	262;256;256	A;T;C	240;236;236	penA.44.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1294	1296	GTG	255;257;259	G;T;G	233;232;236	penA.44.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1294	1296	GTG	255;257;259	G;T;G	233;232;236	penA.44.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1798	1800	ACC	215;211;212	A;C;C,A	199;197;198,1	penA.44.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	T502P	0	.	.	1504	1506	ACG	1852	1854	ACG	210;209;211	A;C;G	175;173;175	penA.44.001:1:1:T502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	T502V	0	.	.	1504	1506	ACG	1852	1854	ACG	210;209;211	A;C;G	175;173;175	penA.44.001:1:1:T502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1975	1977	GGC	176;175;177	G;G;C	162;161;162	penA.44.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1984	1986	GGC	183;183;185	G;G;C	169;167;168	penA.44.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.44.001	penA.44.001	1	1	27	4384	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2296	189.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2002	2004	CTG	188;193;194	C,G;T;G	138,7;140;150	penA.44.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6268	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3080	202.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1679	1681	CCG	244;246;246	C;C;G	204;212;212	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2692	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1862	144.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	562	562	C	211	C	193	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	T26A	NONSYN	76	78	ACC	484	486	GCC	273;270;270	G;C,T;C	241;246,1;244	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	520	522	GAA	254;258;256	G;A;A	236;240;238	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	N124S	NONSYN	370	372	AAT	778	780	AGT	255;253;253	A;G;T	229;231;229	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	808	810	GAT	254;256;257	G;A;T,A	232;234;233,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	931	933	TCA	256;257;255	T,A;C;A	235,1;236;233	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1060	1062	GTC	244;245;246	G;T;C	229;227;232	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1072	1074	TCT	240;240;238	T;C,G;T	230;229,1;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1390	1392	GCA	227;227;226	G;C;A	210;212;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	1	SNP	p	G120K	1	.	.	358	360	AAG	766	768	AAG	247;247;247	A;A;G	226;226;225	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	1	SNP	p	A121D	1	.	.	361	363	GAC	769	771	GAC	248;248;248	G;A;C	224;224;227	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2940	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1598	183.5	1	SNP	p	D121N	0	.	.	361	363	GAC	769	771	GAC	248;248;248	G;A;C	224;224;227	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10774	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4756	225.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1983	1985	CAT	229;230;227	C,T;A;T	218,1;220;217	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1100	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	970	112.7	1	SNP	p	V57M	1	.	.	169	171	ATG	414	416	ATG	233;232;230	A;T;G	214;214;211	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
